ROS1 and neoplasm: In this case, the patient’s most recent tumor assessment showed partial remission, and he has survived for over 30 months since the diagnosis of metastatic lung cancer, which is superior to the median duration of response (DoR) of 13.0 months and the median progression-free survival (PFS) of 12.9 months reported in prior study of entrectinib for ROS1-positive advanced NSCLC (22).